Stimulation of platelet nitric oxide production by nebivolol prevents thrombosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 4, 2014, Pages 820-829

  Momi, Stefania ^a   Caracchini, Roberta ^a   Falcinelli, Emanuela ^a   Evangelista, Stefano ^b   Gresele, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Dept of Pharmacology   (Italy)

Author keywords

bisoprolol; blood platelets; nebivolol; nitric oxide; thrombosis

Indexed keywords

ADRENALIN; BISOPROLOL; COLLAGEN; CYCLIC GMP; NEBIVOLOL; NITRATE; NITRIC OXIDE; NITRITE; PADGEM PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD FLOW; CELL STIMULATION; CONTROLLED STUDY; DEGRADATION; DRUG MECHANISM; ELEVATED BLOOD PRESSURE; ENANTIOMER; ENZYME PHOSPHORYLATION; ERYTHROCYTE; FEMORAL ARTERY; INFERIOR CAVA VEIN; LUNG EMBOLISM; MICROVASCULATURE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; VEIN THROMBOSIS;

BISOPROLOL; BLOOD PLATELETS; NEBIVOLOL; NITRIC OXIDE; THROMBOSIS;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; ANTIOXIDANTS; BENZOPYRANS; BLOOD PLATELETS; BLOOD PRESSURE; CYCLIC GMP; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; FIBRINOLYTIC AGENTS; ISOMERISM; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; SELENOPROTEIN P; THROMBOEMBOLISM; THROMBOSIS; TIME FACTORS; UP-REGULATION;

EID: 84897414549     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303290     Document Type: Article

References (50)

1. Nadar S, Lip GY. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr Pharm Des. 2003;9:1715-1732.
2. Kerry R, Scrutton MC, Wallis RB. Beta-Adrenoceptor antagonists and human platelets: relationship of effects to lipid solubility. Biochem Pharmacol. 1984;33:2615-2622.
3. Mason RP, Giles TD, Sowers JR. Evolving mechanisms of action of beta blockers: focus on nebivolol. J Cardiovasc Pharmacol. 2009;54:123-128.
4. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodila-tory activity of nebivolol, a third generation β-blocker. Blood Pressure. 2006;13: 3-17.
5. Ignarro LJ. Different pharmacological properties of two enantiomers in a unique β-blocker, nebivolol. Cardiovasc Ther. 2008;26:119-134.
6. Pauwels PJ, Van Gompel P, Leysen JE. Human β1-And β2-Adrenergic receptor binding and mediated accumulation of cAMP in transfected chinese hamster ovary cells. Profle of nebivolol and known β-Adrenergic blockers. Biochem Pharmacol. 1991;42:1683-1689.
7. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: evidence for an L-Arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067-1071.
8. Gao YS, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol. 1991;17:964-969.
9. Bakris GL, Basile JN, Giles TD, Taylor AA. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol. Am J Med. 2010;123:S2-S8.
10. Reichenbach G, Momi S, Gresele P. Nitric oxide and its antithrombotic action in the cardiovascular system. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5: 65-74.
11. Emerson M, Momi S, Paul W, Alberti PF, Page C, Gresele P. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature. Thromb Haemost. 1999;81:961-966.
12. Sase K, Michel T. Expression of constitutive endothelial nitric oxide syn-thase in human blood platelets. Life Sci. 1995;57:2049-2055.
13. Radomski MW, Palmer RM, Moncada S. An L-Arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA. 1990;87:5193-5197.
14. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P. Identifcation of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med. 1995;125:370-377.
15. Freedman JE, Sauter R, Battinelli EM, Ault K, Knowles C, Huang PL, Loscalzo J. Defcient platelet-derived nitric oxide and enhanced hemosta-sis in mice lacking the NOSIII gene. Circ Res. 1999;84:1416-1421.
16. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997;100:350-356.
17. Kanaya S, Ikeda H, Haramaki N, Murohara T, Imaizumi T. Intraplatelet tetrahydrobiopterin plays an important role in regulating canine coronary arterial thrombosis by modulating intraplatelet nitric oxide and superoxide generation. Circulation. 2001;104:2478-2484.
18. Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney JF Jr, Vita JA. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation. 1998;98:1481-1486.
19. Falcinelli E, Francisci D, Belfori B, Petito E, Guglielmini G, Malincarne L, Mezzasoma A, Sebastiano M, Conti V, Giannini S, Bonora S, Baldelli F, Gresele P. In vivo platelet activation and platelet hyperre-Activity in abacavir-treated HIV-infected patients. Thromb Haemost. 2013;110:349-357.
20. Falciani M, Rinaldi B, D'Agostino B, Mazzeo F, Rossi S, Nobili B, Rossi F, Filippelli A. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol. 2001;38:922-929.
21. Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb Haemost. 2010;103:56-61.
22. Momi S, Monopoli A, Alberti PF, Falcinelli E, Corazzi T, Conti V, Miglietta D, Ongini E, Minuz P, Gresele P. Nitric oxide enhances the anti-infammatory and anti-Atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. Cardiovasc Res. 2012;94:428-438.
23. Momi S, Emerson M, Paul W, Leone M, Mezzasoma AM, Del Soldato P, Page CP, Gresele P. Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. Eur J Pharmacol. 2000;397:177-185.
24. Rumbaut RE, Slaff DW, Burns AR. Microvascular thrombosis models in venules and arterioles in vivo. Microcirculation. 2005;12:259-274.
25. Atochin DN, Huang PL. Endothelial nitric oxide synthase transgenic models of endothelial dysfunction. Pfugers Arch. 2010;460:965-974.
26. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J. 1989;3:31-36.
27. Maeda H, Akaike T, Yoshida M, Suga M. Multiple functions of nitric oxide in pathophysiology and microbiology: analysis by a new nitric oxide scavenger. J Leukoc Biol. 1994;56:588-592.
28. Marazzi G, Volterrani M, Caminiti G, Iaia L, Cacciotti L, Massaro R, Sposato B, Vitale C, Mercuro G, Rosano G. Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. Adv Ther. 2010;27:655-664.
29. Randriamboavonjy V, Fleming I. Endothelial nitric oxide synthase (eNOS) in platelets: how is it regulated and what is it doing there? Pharmacol Rep. 2005;57 Suppl:59-65.
30. Gambaryan S, Kobsar A, Hartmann S, Birschmann I, Kuhlencordt PJ, Müller-Esterl W, Lohmann SM, Walter U. NO-synthase-/NO-independent regulation of human and murine platelet soluble guanylyl cyclase activity. J Thromb Haemost. 2008;6:1376-1384.
31. Li Z, Xi X, Gu M, Feil R, Ye RD, Eigenthaler M, Hofmann F, Du X. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell. 2003;112:77-86.
32. Iafrati MD, Vitseva O, Tanriverdi K, Blair P, Rex S, Chakrabarti S, Varghese S, Freedman JE. Compensatory mechanisms infuence hemo-stasis in setting of eNOS defciency. Am J Physiol Heart Circ Physiol. 2005;288:H1627-H1632.
33. Ozüyaman B, Gödecke A, Küsters S, Kirchhoff E, Scharf RE, Schrader J. Endothelial nitric oxide synthase plays a minor role in inhibition of arterial thrombus formation. Thromb Haemost. 2005;93:1161-1167.
34. Marjanovic JA, Li Z, Stojanovic A, Du X. Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation. J Biol Chem. 2005;280:37430-37438.
35. Galluccio E, Cassina L, Russo I, et al. A novel truncated form of eNOS associates with altered vascular function. Cardiovasc Res. 2014;101:492-502.
36. Ikeda H, Takajo Y, Murohara T, Ichiki K, Adachi H, Haramaki N, Katoh A, Imaizumi T. Platelet-derived nitric oxide and coronary risk factors. Hypertension. 2000;35:904-907.
37. Erdmann J, Stark K, Esslinger UB, et al.; CARDIoGRAM. Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature. 2013;504:432-436.
38. Broeders MA, Doevendans PA, Bekkers BC, Bronsaer R, van Gorsel E, Heemskerk JW, Egbrink MG, van Breda E, Reneman RS, van Der Zee R. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-Adrenergic receptor-mediated nitric oxide production. Circulation. 2000;102:677-684.
39. Gosgnach W, Boixel C, Névo N, Poiraud T, Michel JB. Nebivolol induces calcium-independent signaling in endothelial cells by a possible beta-Adrenergic pathway. J Cardiovasc Pharmacol. 2001;38:191-199.
40. Evangelista S, Garbin U, Pasini AF, Stranieri C, Boccioletti V, Cominacini L. Effect of DL-nebivolol, its enantiomers and metabolites on the intracel-lular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res. 2007;55:303-309.
41. Ladage D, Brixius K, Hoyer H, Steingen C, Wesseling A, Malan D, Bloch W, Schwinger RH. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol. 2006;33:720-724.
42. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597-601.
43. Signorello MG, Giacobbe E, Passalacqua M, Leoncini G. The anan-damide effect on NO/cGMP pathway in human platelets. J Cell Biochem. 2011;112:924-932.
44. Willoughby SR, Rajendran S, Chan WP, Procter N, Leslie S, Liberts EA, Heresztyn T, Chirkov YY, Horowitz JD. Ramipril sensitizes platelets to nitric oxide: implications for therapy in high-risk patients. J Am Coll Cardiol. 2012;60:887-894.
45. Tran Quang T, Rozec B, Audigane L, Gauthier C. Investigation of the different adrenoceptor targets of nebivolol enantiomers in rat thoracic aorta. Br J Pharmacol. 2009;156:601-608.
46. Erickson CE, Gul R, Blessing CP, Nguyen J, Liu T, Pulakat L, Bastepe M, Jackson EK, Andresen BT. The β-blocker nebivolol is a GRK/β-Arrestin biased agonist. PLoS One. 2013;8:e71980.
47. Laufs U, Gertz K, Huang P, Nickenig G, Böhm M, Dirnagl U, Endres M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in nor-mocholesterolemic mice. Stroke. 2000;31:2442-2449.
48. Tannous M, Cheung R, Vignini A, Mutus B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost. 1999;82:1390-1394.
49. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659-661.
50. Ambrosio G, Flather MD, Böhm M, Cohen-Solal A, Murrone A, Mascagni F, Spinucci G, Conti MG, van Veldhuisen DJ, Tavazzi L, Coats AJ. β-blockade with nebivolol for prevention of acute isch-Aemic events in elderly patients with heart failure. Heart. 2011; 97:209-214.